Mercury Pharmaceuticals

We are de-risking biomedical innovations, while turning biomedical knowledge into social and economic value.

Stay Informed!

LabVantage named a visionary leader in life sciences and industrial LIMS by Frost & Sullivan

21

Sep 2026

LabVantage named a visionary leader in life sciences and industrial LIMS by Frost & Sullivan

LabVantage Solutions, Inc., a leading global provider of laboratory informatics solutions and services, has been named a Visionary Leader in two 2026 Frost Radar™ reports by Frost & Sullivan: Frost Radar™: Life Sciences Laboratory Information Management Systems, 2026 and Frost Radar™: Laboratory Information Management Systems in Industrial Applications, 2026. Announced at LabVantage's Customer Training and Education Conference (CTEC) Europe 2026 in Paris, the dual recognition marks LabVantage's fourth consecutive year of Frost Radar leadership.

Active form of meprin-β protein increases in people with Alzheimer’s disease

21

Sep 2026

Active form of meprin-β protein increases in people with Alzheimer’s disease

A team from the Altered Molecular Mechanism in Alzheimer's Disease and Dementia laboratory, led by Javier Sáez Valero, a researcher at the Institute for Neurosciences (IN), a joint centre of the Miguel Hernández University of Elche (UMH) and the Spanish National Research Council (CSIC), has identified increased levels of the protein meprin-β in the brain and cerebrospinal fluid of people with Alzheimer's disease.

Sugary drinks stood out in this stomach cancer study, but diet drinks did not

21

Sep 2026

Sugary drinks stood out in this stomach cancer study, but diet drinks did not

In two large US prospective cohorts, consuming more than one sugar-sweetened beverage a day was associated with higher gastric cancer incidence compared with consuming less than one serving a month. Artificially sweetened beverages were not associated with gastric cancer incidence, and the authors called for further studies to confirm the findings and clarify possible biological mechanisms.

Measles outbreaks may reveal more than gaps in vaccination

21

Sep 2026

Measles outbreaks may reveal more than gaps in vaccination

A commentary in Human Vaccines & Immunotherapeutics argues that measles outbreaks can serve as a sensitive indicator of weaknesses in vaccination coverage, surveillance, health equity, community trust, and broader immunization systems. The authors contend that pursuing measles eradication could also strengthen routine immunization, laboratory capacity, outbreak preparedness, and health-system resilience.

A 194-country analysis reveals gaps in how late childhood vaccinations are tracked

21

Sep 2026

A 194-country analysis reveals gaps in how late childhood vaccinations are tracked

A global analysis of WHO/UNICEF data from 194 countries found wide variation in countries’ ability to record delayed childhood vaccinations, with 64% of reporting countries saying they could capture late doses in 2022. Following birth cohorts over time and adding delayed MCV1 doses raised median coverage estimates by 3.6 to 5.1 percentage points across available cohort years, though incomplete and inconsistent reporting limited confidence in some estimates.

MERCURY trials

Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more

Cancer

Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more

Neuroscience

Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more

Mercury Pharmaceuticals

Why Us?

Strong experience in academic research and technology transfer makes us understand your goals and motivations as a technology originator.
Our experience in drug development from discovery to clinical and commercial stages makes us an insider player within the biopharmaceutical industry.
Smart approach to project management that helps speed up development stages and decision making.
Availability of own investment up to 2m€ per project allows us to reach the next value milestone.